NCT07043608 2025-07-02
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting
Clinical Trials
47 trialsNCT03336983 2024-08-01
BonEnza
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT00268476 2023-04-18
STAMPEDE
Medical Research Council
Phase 2/3 Active not recruiting
NCT03408652 2021-10-22
MOSCAR
Centre Leon Berard
Phase 3 Terminated
NCT00058188 2020-12-08
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
Northwestern University
Phase 3 Terminated
NCT00079001 2020-05-12
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00226954 2020-03-18
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Stanford University
Phase 2 Terminated
NCT00582556 2019-11-26
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
University of Wisconsin, Madison
Phase 2 Completed
NCT00582790 2019-11-25
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT01006395 2019-07-05
Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Austin Health
Phase 2/3 Completed
NCT01205646 2019-04-12
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00869206 2018-11-07
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00329797 2017-11-29
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00193856 2017-10-12
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
Trans Tasman Radiation Oncology Group
Phase 3 Completed
NCT00375648 2017-06-02
TRAPEZE
Novartis
Phase 3 Completed
NCT00219271 2017-05-31
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Novartis
Phase 4 Completed
NCT00172055 2017-03-06
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
Novartis
Phase 3 Completed
NCT00171639 2017-02-23
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
Novartis
Phase 3 Completed
NCT00237146 2017-02-23
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
Novartis
Phase 4 Completed
NCT00242554 2017-02-23
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
Novartis
Phase 4 Completed
NCT00434317 2017-02-23
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00334139 2017-02-07
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Novartis
Phase 4 Completed
NCT00172003 2016-11-18
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
Novartis
Phase 4 Completed
NCT00391690 2016-11-18
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Novartis
Phase 4 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00685646 2015-10-16
ZAPCA
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 3 Completed
NCT00151073 2015-01-22
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00242567 2014-05-07
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
Novartis
Phase 3 Completed
NCT00489905 2013-10-23
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Hospital Authority, Hong Kong
Phase NA Completed
NCT00554918 2013-08-07
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00181584 2013-07-11
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00588913 2013-07-10
Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00004928 2013-06-19
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00039104 2013-06-05
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005073 2013-05-01
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
Novartis
Phase 3 Terminated
NCT00490698 2013-03-18
Zoledronate With Atorvastatin in Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00172016 2012-04-30
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
Novartis
Phase 4 Completed
NCT00029224 2012-02-01
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
Phase 4 Completed
NCT00181558 2010-05-10
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
Massachusetts General Hospital
Phase 2 Completed
NCT00258765 2010-04-26
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
Novartis
Phase 2 Terminated
NCT00415779 2010-02-24
ZANTE
National Cancer Institute, Naples
Phase 1 Completed
NCT00035997 2009-11-23
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
Novartis
Phase 4 Completed
NCT00087659 2009-11-23
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
Novartis
Phase NA Completed
NCT00391950 2009-11-23
Maintaining Bone Strength in Men With Prostate Cancer
Novartis
Phase 3 Terminated
NCT00636740 2009-02-20
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
Merrion Pharmaceuticals, LLC
Phase 2 Completed
NCT00072930 2008-01-15
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
MedImmune LLC
Phase 2 Completed
NCT00520052 2007-08-23
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
Wirral University Teaching Hospital NHS Trust
Phase NA Completed